CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Agios Pharmaceuticals, Inc. - AGIO CFD

28.95
0.59%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.11
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Agios Pharmaceuticals Inc ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 28.78
Open* 28.87
1-Year Change* 32.31%
Day's Range* 28.87 - 29.27
52 wk Range 19.80-31.56
Average Volume (10 days) 685.69K
Average Volume (3 months) 13.01M
Market Cap 1.19B
P/E Ratio -100.00K
Shares Outstanding 55.89M
Revenue 24.03M
EPS -3.95
Dividend (Yield %) N/A
Beta 0.76
Next Earnings Date Feb 21, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 16, 2024 28.78 -0.12 -0.42% 28.90 29.48 28.49
Apr 15, 2024 29.06 -0.46 -1.56% 29.52 29.63 28.61
Apr 12, 2024 29.44 -0.54 -1.80% 29.98 30.55 28.61
Apr 11, 2024 30.59 0.83 2.79% 29.76 30.97 29.25
Apr 10, 2024 29.86 0.92 3.18% 28.94 30.19 28.82
Apr 9, 2024 29.66 2.27 8.29% 27.39 29.75 27.33
Apr 8, 2024 27.62 0.09 0.33% 27.53 27.82 27.04
Apr 5, 2024 27.36 0.15 0.55% 27.21 28.20 27.06
Apr 4, 2024 27.84 -0.40 -1.42% 28.24 28.81 27.59
Apr 3, 2024 28.41 0.64 2.30% 27.77 28.51 27.77
Apr 2, 2024 28.57 0.60 2.15% 27.97 28.90 27.73
Apr 1, 2024 28.81 -0.32 -1.10% 29.13 29.29 28.57
Mar 28, 2024 29.17 0.46 1.60% 28.71 29.37 28.70
Mar 27, 2024 29.08 0.13 0.45% 28.95 29.38 28.49
Mar 26, 2024 29.02 -0.15 -0.51% 29.17 30.04 28.77
Mar 25, 2024 29.61 0.33 1.13% 29.28 30.10 29.28
Mar 22, 2024 29.68 -0.28 -0.93% 29.96 30.53 29.68
Mar 21, 2024 30.15 0.19 0.63% 29.96 31.25 29.96
Mar 20, 2024 30.18 0.49 1.65% 29.69 30.63 29.62
Mar 19, 2024 29.90 0.90 3.10% 29.00 30.34 28.67

Agios Pharmaceuticals, Inc. Events

Time (UTC) Country Event
Thursday, May 2, 2024

Time (UTC)

12:30

Country

US

Event

Q1 2024 Agios Pharmaceuticals Inc Earnings Release
Q1 2024 Agios Pharmaceuticals Inc Earnings Release

Forecast

-

Previous

-
Thursday, August 1, 2024

Time (UTC)

12:30

Country

US

Event

Q2 2024 Agios Pharmaceuticals Inc Earnings Release
Q2 2024 Agios Pharmaceuticals Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 14.24 0 0 0 94.387
Revenue 14.24 94.387
Total Operating Expense 265.583 371.779 335.916 316.269 456.866
Selling/General/Admin. Expenses, Total 121.673 121.445 115.105 102.007 114.145
Research & Development 279.91 256.973 220.811 214.262 341.324
Operating Income -251.343 -371.779 -335.916 -316.269 -362.479
Interest Income (Expense), Net Non-Operating 12.793 0.836 6.611 14.861 16.451
Net Income Before Taxes -231.801 -356.51 -329.305 -301.408 -346.028
Net Income After Taxes -231.801 -356.51 -329.305 -301.408 -346.028
Net Income Before Extra. Items -231.801 -356.51 -329.305 -301.408 -346.028
Net Income -231.801 1604.71 -327.37 -411.472 -346.028
Total Adjustments to Net Income
Income Available to Common Excl. Extra. Items -231.801 -356.51 -329.305 -301.408 -346.028
Income Available to Common Incl. Extra. Items -231.801 1604.71 -327.37 -411.472 -346.028
Diluted Net Income -231.801 1604.71 -327.37 -411.472 -346.028
Diluted Weighted Average Shares 54.7894 60.4473 68.9979 59.9945 57.4183
Diluted EPS Excluding Extraordinary Items -4.23076 -5.89786 -4.77268 -5.02392 -6.02644
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS -6.74409 -6.00769 -4.77268 -5.02392 -6.02644
Total Extraordinary Items 0 1961.22 1.935 -110.064
Cost of Revenue, Total 1.704 1.397
Gross Profit 12.536 92.99
Unusual Expense (Income) -137.704 -6.639 0 0
Other, Net 6.749 14.433 0 0
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 6.712 5.609 4.31 3.516 5.582
Total Operating Expense 100.412 96.222 -24.371 90.163 100.518
Selling/General/Admin. Expenses, Total 30.409 28.367 32.771 29.123 28.264
Research & Development 68.895 67.301 70.298 64.966 74.523
Operating Income -93.7 -90.613 28.681 -86.647 -94.936
Interest Income (Expense), Net Non-Operating 8.254 8.091 6.488 3.818 1.793
Net Income Before Taxes -83.806 -81.018 36.526 -81.747 -91.806
Net Income After Taxes -83.806 -81.018 36.526 -81.747 -91.806
Net Income Before Extra. Items -83.806 -81.018 36.526 -81.747 -91.806
Total Extraordinary Items 0 0 0
Net Income -83.806 -81.018 36.526 -81.747 -91.806
Income Available to Common Excl. Extra. Items -83.806 -81.018 36.526 -81.747 -91.806
Income Available to Common Incl. Extra. Items -83.806 -81.018 36.526 -81.747 -91.806
Diluted Net Income -83.806 -81.018 36.526 -81.747 -91.806
Diluted Weighted Average Shares 55.6043 55.2654 54.9548 54.8446 54.7997
Diluted EPS Excluding Extraordinary Items -1.50718 -1.46598 0.66465 -1.49052 -1.6753
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -1.50718 -1.46598 -1.66186 -1.57153 -1.72465
Unusual Expense (Income) 0 0 -127.853 -4.443 -2.704
Other, Net 1.64 1.504 1.357 1.082 1.337
Revenue 6.712 5.609 4.31 3.516 5.582
Cost of Revenue, Total 1.108 0.554 0.413 0.517 0.435
Gross Profit 5.604 5.055 3.897 2.999 5.147
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 832.772 1064.23 636.677 611.704 613.78
Cash and Short Term Investments 783.119 1020.02 572.929 564.877 585.302
Cash & Equivalents 139.259 203.126 127.436 80.931 70.502
Short Term Investments 643.86 816.892 445.493 483.946 514.8
Total Receivables, Net 2.206 4.378 25.399 15.319 10.442
Prepaid Expenses 38.955 39.835 23.651 24.177 17.167
Total Assets 1238.72 1437.74 852.952 890.741 858.457
Property/Plant/Equipment, Total - Net 88.116 104.23 117.542 126.108 24.32
Property/Plant/Equipment, Total - Gross 138.186 149.204 158.895 158.22 50.472
Accumulated Depreciation, Total -50.07 -44.974 -41.353 -32.112 -26.152
Long Term Investments 313.874 266.375 97.608 152.929 220.119
Other Long Term Assets, Total 3.956 2.9 1.125 0 0.238
Total Current Liabilities 62.629 59.826 94.394 92.886 93.503
Accounts Payable 18.616 16.7 26.844 21.896 17.88
Accrued Expenses 44.013 42.795 67.233 59.784 42.147
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0 0 10.933 33.476
Total Liabilities 137.904 145.761 453.452 250.213 170.92
Total Long Term Debt 0 0.276 0.331 0.673 0
Other Liabilities, Total 75.275 85.659 358.727 156.654 77.417
Total Equity 1100.81 1291.97 399.5 640.528 687.537
Common Stock 0.071 0.071 0.069 0.068 0.058
Additional Paid-In Capital 2386.32 2334.35 2242.8 2156.36 1794.28
Retained Earnings (Accumulated Deficit) -470.561 -238.76 -1843.47 -1516.1 -1104.63
Other Equity, Total -12.535 -1.198 0.105 0.202 -2.171
Total Liabilities & Shareholders’ Equity 1238.72 1437.74 852.952 890.741 858.457
Total Common Shares Outstanding 55.0397 54.3342 69.2939 68.4011 58.2187
Accounts Receivable - Trade, Net 2.206 21.328 11.852 7.31
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Total Inventory 8.492 14.698 7.331 0.869
Current Port. of LT Debt/Capital Leases 0 0.331 0.317 0.273
Capital Lease Obligations 0 0.276 0.331 0.673
Total Preferred Shares Outstanding 0 0 0 0
Other Current Assets, Total 0
Treasury Stock - Common -802.486 -802.486
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 704.352 757.239 791.656 832.772 784.935
Cash and Short Term Investments 647.488 702.566 739.201 783.119 727.68
Cash & Equivalents 64.333 84.753 104.139 139.259 122.449
Short Term Investments 583.155 617.813 635.062 643.86 605.231
Prepaid Expenses 38.414 36.751 39.303 38.955 46.487
Other Current Assets, Total
Total Assets 1007.26 1085.15 1151.3 1238.72 1180.32
Property/Plant/Equipment, Total - Net 73.947 79.5 83.959 88.116 93.13
Long Term Investments 224.902 244.357 271.727 313.874 298.352
Other Long Term Assets, Total 4.057 4.057 3.956 3.956 3.903
Total Current Liabilities 58.425 55.141 45.113 62.629 53.596
Accounts Payable 13.271 11.626 8.662 18.616 10.415
Accrued Expenses 45.154 43.515 36.451 44.013 43.098
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0 0.083
Other Current Liabilities, Total
Total Liabilities 120.415 120.917 114.772 137.904 130.15
Total Long Term Debt 0 0 0 0 1.055
Capital Lease Obligations 0 1.055
Other Liabilities, Total 61.99 65.776 69.659 75.275 75.499
Total Equity 886.843 964.236 1036.53 1100.81 1050.17
Preferred Stock - Non Redeemable, Net 0 0 0 0
Common Stock 0.072 0.072 0.072 0.071 0.071
Additional Paid-In Capital 2421.86 2410.91 2398.93 2386.32 2374.75
Retained Earnings (Accumulated Deficit) -726.709 -635.385 -551.579 -470.561 -507.087
Other Equity, Total -5.896 -8.87 -8.411 -12.535 -15.083
Total Liabilities & Shareholders’ Equity 1007.26 1085.15 1151.3 1238.72 1180.32
Total Common Shares Outstanding 55.884 55.7348 55.5414 55.0397 54.894
Total Preferred Shares Outstanding 0 0 0 0
Total Receivables, Net 1.176 2.251 1.778 2.206 5.592
Treasury Stock - Common -802.486 -802.486 -802.486 -802.486 -802.486
Accounts Receivable - Trade, Net 1.176 2.251 1.778 2.206 1.818
Total Inventory 17.274 15.671 11.374 8.492 5.176
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -231.801 1604.71 -327.37 -411.472 -346.028
Cash From Operating Activities -309.478 -407.32 -290.759 -370.622 -304.421
Cash From Operating Activities 8.564 9.24 9.984 8.087 7.172
Non-Cash Items -69.808 -1984.45 97.664 78.762 69.54
Cash Taxes Paid
Changes in Working Capital -16.433 -36.822 -71.037 -45.999 -35.105
Cash From Investing Activities 243.261 1248.78 75.746 91.44 -273.825
Capital Expenditures -4.881 -5.741 -14.909 -12.171 -6.986
Other Investing Cash Flow Items, Total 248.142 1254.52 90.655 103.611 -266.839
Cash From Financing Activities 2.35 -765.768 261.518 289.611 546.024
Financing Cash Flow Items 0 0 250.537 0 -0.391
Issuance (Retirement) of Stock, Net 2.681 -765.19 11.317 289.724 546.415
Net Change in Cash -63.867 75.69 46.505 10.429 -32.222
Issuance (Retirement) of Debt, Net -0.331 -0.578 -0.336 -0.113
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -81.018 -231.801 -268.327 -186.58 -94.774
Cash From Operating Activities -95.183 -309.478 -243.315 -171.964 -97.735
Cash From Operating Activities 1.79 8.564 6.75 4.769 2.478
Non-Cash Items 9.821 -69.808 46.013 32.986 19.096
Changes in Working Capital -25.776 -16.433 -27.751 -23.139 -24.535
Cash From Investing Activities 57.596 243.261 160.31 56.24 -26.573
Capital Expenditures -0.399 -4.881 -4.768 -4.73 -2.804
Other Investing Cash Flow Items, Total 57.995 248.142 165.078 60.97 -23.769
Cash From Financing Activities 2.467 2.35 2.328 1.141 1.208
Issuance (Retirement) of Stock, Net 2.467 2.681 2.576 1.305 1.289
Issuance (Retirement) of Debt, Net 0 -0.331 -0.248 -0.164 -0.081
Net Change in Cash -35.12 -63.867 -80.677 -114.583 -123.1
Financing Cash Flow Items 0 0 0 0

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Agios Pharmaceuticals, Inc. Company profile

About Agios Pharmaceuticals Inc

Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of a- and b-thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD and anemia associated with low-to intermediate-risk myelodysplastic syndrome (L-IR MDS), which is in Phase I clinical study.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Agios Pharmaceuticals Inc revenues was not reported. Net loss before extraordinary items increased 8% to $356.5M. Higher net loss reflects Research and development increase of 20% to $232.4M (expense), General and administrative increase of 15% to $92.5M (expense), Interest Income decrease of 87% to $836K (income). Basic Earnings per Share excluding Extraordinary Items decreased from -$4.77 to -$5.90.

Equity composition

Common Stock $.001 Par, Shares auth and O/s after the offering: 78.3 M auth., 29,380,399 issd. Insider Owns approx.38.04%.(After the IPO) IPO:TBA.

Industry: Bio Therapeutic Drugs

88 Sidney Street
CAMBRIDGE
MASSACHUSETTS 02139
US

Income Statement

  • Annual
  • Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

People also watch

XRP/USD

0.49 Price
-1.380% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

BTC/USD

61,145.15 Price
-3.170% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

US100

17,545.20 Price
-1.020% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

ETH/USD

2,963.15 Price
-3.610% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading